CDK2
Cyclin-dependent kinase 2
As of the edition of 20 October 2026, CDK2 (cyclin-dependent kinase 2, UniProt P24941) has 21 drugs tested at it and 20 companies on the list, 13 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P24941
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 524
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Urinary and reproductive; Hormones; Pregnancy and women's health; Digestive system
- Registered trials of its drugs
- 152
Drugs at this target
| Status | Count |
|---|---|
| Active | 5 |
| Went quiet | 2 |
| Stopped | 12 |
| Status not established | 2 |
| Total | 21 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Alvocidib | Stopped | Phase 2 | none listed |
| UCN-01 | Stopped | Phase 2 | none listed |
| Dinaciclib | Stopped | Phase 3 | none listed |
| INCB123667 | Active | Phase 3 | none listed |
| Culmerciclib | Status not established | Phase 2 | none listed |
| Seliciclib | Stopped | Phase 2 | none listed |
| Zotiraciclib | Stopped | Phase 2 | none listed |
| Milciclib | Stopped | Phase 2 | none listed |
| NUV-422 | Stopped | Phase 2 | none listed |
| AVZO-021 | Active | Phase 2 | none listed |
| BMS-387032 | Went quiet | Phase 1 | none listed |
| Tegtociclib | Active | Phase 2 | none listed |
12 of 21 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 13 |
| Engaged | 6 |
| Undetermined | 1 |
| Total on the list | 20 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
| Nuvation Bio | Route A |
| Sanofi | Route A |
The other 17 companies at CDK2
In the product20 companies in all; 17 are not named here, and no score is.
See the 20 companies at CDK2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.